Showing results (141-150 of 181) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerF Loupakis, C Cremolini, L Salvatore, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE studyY J Kim, P Merle, R S Finn, et al.
Journal of Biological Regulators and Homeostatic Agents|July 20, 2021
Geographic tongue clinical response in moderate-to-severe psoriatic patients undergoing secukinumab: a real-life, multicenter retrospective observational studyG Damiani, A Pacifico, P Malagoli, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution studyV Massa, F Signorini, F Salani, et al.
British Journal of Cancer|August 30, 2008
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapyF Graziano, A Ruzzo, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)L Fornaro, S Lonardi, G Masi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 4, 2015
Phylogenetic characterization of Central/Southern European lineage 2 West Nile virus: analysis of human outbreaks in Italy and Greece, 2013-2014L Barzon, A Papa, E Lavezzo, et al.
Journal of Biological Regulators and Homeostatic Agents|July 20, 2021
Cutaneous and oral comorbidities in patients with geographic tongue: a multicenter multidisciplinary cross-sectional observational studyG Damiani, L C Gironi, A Pacifico, et al.
ESMO Open|October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONOD Rossini, A Boccaccino, A Sbrana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trialG Masi, L Salvatore, L Boni, et al.
Pageof 19